Advertisement
UK markets closed

  • FTSE 100

    8,139.83
    +60.97 (+0.75%)
     

  • FTSE 250

    19,824.16
    +222.18 (+1.13%)
     

  • AIM

    755.28
    +2.16 (+0.29%)
     

  • GBP/EUR

    1.1678
    +0.0022 (+0.19%)
     

  • GBP/USD

    1.2498
    -0.0013 (-0.10%)
     

  • Bitcoin GBP

    51,253.79
    -360.14 (-0.70%)
     

  • CMC Crypto 200

    1,332.56
    -63.98 (-4.58%)
     

  • S&P 500

    5,106.15
    +57.73 (+1.14%)
     

  • DOW

    38,302.46
    +216.66 (+0.57%)
     

  • CRUDE OIL

    83.68
    +0.11 (+0.13%)
     

  • GOLD FUTURES

    2,352.30
    +9.80 (+0.42%)
     

  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     

  • HANG SENG

    17,651.15
    +366.61 (+2.12%)
     

  • DAX

    18,161.01
    +243.73 (+1.36%)
     

  • CAC 40

    8,088.24
    +71.59 (+0.89%)
     
PROPERTY:

9 luxury homes to consider if money is no object

Ever thought about what a multimillion pound budget would buy you?

Company News For Dec 5, 2017

Zacks Equity Research
Updated
Is (PSEC) Outperforming Other Finance Stocks This Year?

  • Aetna Inc’s AET shares decreased 1.4% after CVS Health CVS announced it was buying the healthcare benefits giant for around $69 billion

  • Shares of General Cable Corporation BGC climbed 35.1% after the company agreed to be acquired by Prysmian Groupfor $1.5 billion or $30 per share

  • Foundation Medicine, Inc’s FMI shares fell 0.6% after its subsidiary unit won the approval of the U.S. Food and Drug Administration for a cancer test

  • Shares of Exactech, Inc. EXAC jumped 19.1% after the company agreed to be taken over by TPG Capital for $737 million or $49.25 a share


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Foundation Medicine, Inc. (FMI) : Free Stock Analysis Report
 
Exactech, Inc. (EXAC) : Free Stock Analysis Report
 
Aetna Inc. (AET) : Free Stock Analysis Report
 
CVS Health Corporation (CVS) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research